BMS wins European Evotaz approval; AMRI buys Gadea for $174M;

@FiercePharma: PetCure Spots Booming Market For Radiosurgery in Pets With Cancer. FierceAnimalHealth article | Follow @FiercePharma

@CarlyHFierce: Endo whistleblower nabs $33.6M from feds for 'extraordinary' work in FCA suit. Story | Follow @CarlyHFierce

> The European Commission (EC) has approved Bristol-Myers Squibb's ($BMY) Evotaz in combination with other antiretroviral agents for the treatment of HIV-1. Report

> AMRI ($AMRI) has purchased Spain's Gadea Pharmaceutical Group for $174 million. Report

> Pfizer ($PFE) has agreed to hand over email chains between its expert witness in the Zoloft multi-district litigation and authors of studies on the risks of the med. Report

Medical Device News

@FierceMedDev: Illumina launches new lab service for HiSeq X sequencing systems. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Malaysian government approves 11 med tech projects worth $120M+. Report | Follow @VarunSaxena2

@EmilyWFierce: Cardiologists weigh in on #FDA's device oversight and 21st Century Cures Act. NYT story | Follow @EmilyWFierce

> EU funds development of a photonic-laser point-of-care cancer Dx device. More

> FDA approves the first implantable, above-the-knee prosthesis. Story

Biotech News

@FierceBiotech: Singapore's big biotech push yields its first clinical contender. Story | Follow @FierceBiotech

@JohnCFierce: Interesting data points coming up on Alzheimer's, a field that makes giddy enthusiasts out of virtually all biz journalists. #odd | Follow @JohnCFierce

> Pint-sized biotechs join the IPO queue as Wall Street cash pours in. More

> Torrid pace of VC investing in H1 sets a new biotech record. News

> Lilly and Biogen prep make-or-break Alzheimer's data amid an amyloid renaissance. Article

And Finally... Wild starlings are ingesting worms that have taken in chemicals from Prozac--and it's changing their behavior. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.